<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832635</url>
  </required_header>
  <id_info>
    <org_study_id>B2016-005-01</org_study_id>
    <nct_id>NCT02832635</nct_id>
  </id_info>
  <brief_title>A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases</brief_title>
  <official_title>Effectiveness and Safety of Whole-brain Radiotherapy With/Without TMZ Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases: a Multi-institutional, Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects on neurocognitive function of
      whole-brain radiotherapy (WBRT) with/without TMZ concurrent chemotherapy or avoidance of
      hippocampus for patients of brain metastases, as well as the feasibility and risk of
      avoidance of hippocampus during whole-brain radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II randomized clinical trial. It is reported that avoidance of hippocampus
      during whole-brain radiotherapy (WBRT) had benefits in preservation of memory for patients,
      and the use of concurrent TMZ in radiotherapy for patients with brain metastases benefited
      for treating outcome.

      The purpose of this study is to evaluate the effects on neurocognitive function of
      whole-brain radiotherapy with/without TMZ concurrent chemotherapy or avoidance of hippocampus
      for patients of brain metastases, as well as the feasibility and risk of avoidance of
      hippocampus during whole-brain radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of neurocognitive function between baseline and 4 months after radiotherapy</measure>
    <time_frame>baseline; four months after radiotherapy</time_frame>
    <description>Neurocognitive function is evaluated by Minimum Mental State Examination (MMSE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on response rate</measure>
    <time_frame>baseline; One, two, four, six, and twelve months after radiotherapy</time_frame>
    <description>Response is evaluated on basis of RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The tolerance of radiotherapy with TMZ concurrent chemotherapy</measure>
    <time_frame>baseline; once a week through during radiotherapy, up to 3 weeks</time_frame>
    <description>Adverse effects are evaluated by CTCAE 4.0 criteria</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Brain Metastasis</condition>
  <condition>Radiation Therapy Complication</condition>
  <arm_group>
    <arm_group_label>WBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with brain metastases (＞3 lesions) ; Whole-brain radiotherapy without avoidance of hippocampus applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBRT with avoidance of hippocampus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with brain metastases (＞3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBRT with TMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with brain metastases (＞3 lesions) ; Whole-brain radiotherapy with concurrent TMZ chemotherapy applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBRT with avoidance of hippocampus and TMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with brain metastases (＞3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus and concurrent TMZ chemotherapy applied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMZ</intervention_name>
    <description>TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy</description>
    <arm_group_label>WBRT with TMZ</arm_group_label>
    <arm_group_label>WBRT with avoidance of hippocampus and TMZ</arm_group_label>
    <other_name>temozolomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBRT with avoidance of hippocampus</intervention_name>
    <description>Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.</description>
    <arm_group_label>WBRT with avoidance of hippocampus</arm_group_label>
    <arm_group_label>WBRT with avoidance of hippocampus and TMZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBRT without avoidance of hippocampus</intervention_name>
    <description>Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.</description>
    <arm_group_label>WBRT</arm_group_label>
    <arm_group_label>WBRT with TMZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary lesions diagnosed by pathology or cytology

          -  Brain metastases confirmed by brain MRI or CT(＞3 brain metastases）

          -  Brain metastases beyond 5mm of hippocampus

          -  Male or female patients with age between 18 and 75 years old

          -  Karnofsky Performance Scores ≥ 60

          -  Expected survival ≥ 6 months

          -  No previous brain surgery or brain radiotherapy

          -  Without dysfunction of heart, lung, liver, kidney and hematopoiesis

          -  The primary carcinoma is under control

        Exclusion Criteria:

          -  MMSE score ＜27

          -  Dysfunction of heart, lung, liver, kidney or hematopoiesis

          -  Severe neurological, mental or endocrine diseases

          -  History of alcohol or drug abuse within 3 months

          -  Visual or hearing dysfunction, low education level, or other reasons leading to not
             capable of taking the MMSE test

          -  Currently under treatment may effect patients' neurocognitive functions

          -  Patients participated in clinical trials of other drugs within last 3 months

          -  Other unsuitable reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun-fei Xia, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Sun Yat-Sen University Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yun-fei Xia, Professor</last_name>
    <phone>86-13602805461</phone>
    <email>xiayf@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaohui Wang, MD</last_name>
    <phone>86-18826260661</phone>
    <email>wangxh@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yun-fei Xia, Professor</last_name>
      <phone>86-13602805461</phone>
      <email>xiayf@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiaohui Wang, MD</last_name>
      <phone>86-18826260661</phone>
      <email>wangxh@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Yun-fei Xia, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaohui Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Three Nine Brain Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin-bo Cai, Prof.</last_name>
      <phone>86-13503030491</phone>
    </contact>
    <investigator>
      <last_name>Linbo Cai, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guo-long Liu, Prof.</last_name>
      <phone>86-13802527172</phone>
    </contact>
    <investigator>
      <last_name>Guo-long Liu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou People's Liberation Army Hospital 421</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Si-Lang Zhou, Prof.</last_name>
      <phone>86-13189099597</phone>
    </contact>
    <investigator>
      <last_name>Si-Lang Zhou, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Panyu Central Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiao-long Cao, Prof.</last_name>
      <phone>86-18922238053</phone>
    </contact>
    <investigator>
      <last_name>Xiao-long Cao, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi-ou Wang, Prof.</last_name>
      <phone>86-13602751067</phone>
    </contact>
    <investigator>
      <last_name>Yi-ou Wang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Cancer Hospital Of Guangzhou Medical Collage</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xun-fan Shao, Prof.</last_name>
      <phone>+86-13902770926</phone>
      <email>xunfanshao@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Xun-fan Shao, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Hospital Of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gong Li, Prof.</last_name>
      <phone>+86-13802915171</phone>
      <email>leegong@21cn.com</email>
    </contact>
    <investigator>
      <last_name>Gong Li, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Guangzhou Medical Collage</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dao-li Niu, Prof.</last_name>
      <phone>+86-13711101855</phone>
      <email>daoliniu@163.com</email>
    </contact>
    <investigator>
      <last_name>Dao-li Niu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <zip>519000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhibin Cheng, Professor</last_name>
      <phone>86-13926946708</phone>
    </contact>
    <investigator>
      <last_name>Zhibin Cheng, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yun-fei Xia</investigator_full_name>
    <investigator_title>Director of Department of Radiation Oncology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>brain metastasis</keyword>
  <keyword>whole-brain radiotherapy</keyword>
  <keyword>TMZ</keyword>
  <keyword>avoidance of hippocampus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

